Cryoconservation during allogeneic hematopoietic Stem cell transplantation FRESH-PEF3107-en Régis PEFFAULT DE LATOUR Cryoconservation during allogeneic hematopoietic Stem cell transplantation CRYOSTEM FRESH-PEF3107-en 3107 FRESH-PEF3107 Régis PEFFAULT DE LATOUR Julie AGOPIAN Emilie ROBERT Boris CALMELS ASSOCIATION CRYOSTEM Epidemiology France Portal (PEF) AGENCE NATIONALE DE LA RECHERCHE (ANR) INSTITUT NATIONAL DU CANCER (INCA) null Julie;AGOPIAN Emilie;ROBERT Graft-versus-host-disease GvHD Allogeneic Hematopoietic Stem Cell Transplantation HSCT Biobanking network Complications Oncology Hematology Clinical immunology Infectious disease medicine Paediatrics Graft-versus-host disease Healthcare system determinants: Use of care Healthcare system determinants The goal of CryoStem is to create a national, multicenter, prospectie, longitudinal, standardized HSCT human-sample collection (derived from adult and pediatric patients) with the purpose of enabling better characterization and prediction of HSCT complications occurence and outcome, including GvHD. CryoStem has generated a French network involving all the French transplant units, adult and pediatric and 28 Biological Resources Centres. Only in a network such as this may the full potential be realized of having concrete and effective interactions between scientists with top knowledge in specific areas and physicians. CryoStem fosters interactions among internationally recognized experts in advanced biotechnology (genomics,transcriptomics, proteomics, and flow cytometry). Altogether, CryoStem provides a structured approach for a range of different research activities, bringing together leading-edge researchers who can access documented biological (CryoStem) and clinical (ProMISe) samples from transplanted patients in order to better characterize and predict HSCT complications. null France Individuals Patients population Male Female Infant, Newborn (birth to 28 days) Infant (28 days to 2 years) Child, Preschool (2 to 5 years) Child (6 to 12 years) Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Any patient suffering from a severe blood disease or blood cancer (leukemia, lymphoma, aplastic anemia...) justifying a first HSCT in one of the transplant units of CRYOSTEM network. Clinical data Biological data Sampling and sending / blood samples reception and processing / provision Health event/morbidity Health event/mortality Other Through organizations (health services or institutions schools businesses etc.) [1000-10000[ individuals Converting or copying information into a structured record Observational Study Observational Study Cohort study 6 455 patients and 2 482 donors as of December 2021, 31 Unknown Restricted access Any investigator selected by CRYOSTEM Scientific Committee commits himself to respect the general terms of the current call of projects to access the collection biological resources. The investigator could access to demographical and clinical information, extracted from the European register of the EBMT (European Society for Blood and Marrow Transplantation), provided via an Excel file made anonymous. Once selected, CRYOSTEM project managers schedule interviews with the investigators in order to identify and select the samples of interest. The delay of provision depend on the number of the samples waited for. Access on specific project only